600200 Share Price Performance
CN¥0.95
-10.09 (-91.39%)
Price CN¥0.95
Share PriceCN¥0.95
JiangSu WuZhong Pharmaceutical Development Co., Ltd.'s (SHSE:600200) Shares Lagging The Industry But So Is The Business
Feb 27
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
600200 Community Narratives
There are no narratives available yet.
Recent 600200 News & Updates
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Oct 31, 2025
- Earnings per share (EPS)
- 0.0023
- Gross Margin
- 60.76%
- Net Profit Margin
- 0.12%
- Debt/Equity Ratio
- 84.0%
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Competitors
Snowflake Analysis
About 600200
- Founded
- 1994
- Employees
- 1096
- CEO
- WebsiteView website
JiangSu WuZhong Pharmaceutical Development Co., Ltd. engages in pharmaceutical, medical cosmetology, investment, and other industries in China and internationally. It provides genetic and chemical drugs in the fields of anti-virus, anti infection, immune regulation, anti-tumor, digestive system, cardiovascular, etc.; and modern traditional Chinese medicine. The company also offers high-end injection filling products for medical cosmetology. It offers its products in various forms, such as hard capsules, granules, tablets, oral solutions, dropping pills, emulsions, large-volume injections, and small-volumes injections, powder injections, freeze-dried powder injections and raw materials, and other dosage forms. The company was founded in 1994 and is based in Suzhou, China.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Chinese Market Performance
- 7 Days: 1.8%
- 3 Months: 18.4%
- 1 Year: 24.1%
- Year to Date: 26.2%
In the last week, the market is up 1.8% led by Industrials sector. In the last year, the market has climbed 24%. As for the next few years, earnings are expected to grow by 27% per annum. Market details ›